| |
|
|
|
|
|
 |
| |
|
³ë¹Ù·º½ºÄ°¼¿200mg NOBAREX CAP. 200MG[Sulfamethoxypyridazine , Trimethoprim]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A29400401]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ݼ¿(2007.03.01)(ÇöÀç¾à°¡)
\29 ¿ø/1ݼ¿(2002.12.31)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹é»ö ºÐ¸»À» ÇÔÀ¯ÇÑ »ó, ÇÏ Àû»öÀÇ Ä°¼¿Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
10ĸ½¶, 100ĸ½¶, 500ĸ½¶, 1000ĸ½¶ |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
À¯È¿±ÕÁ¾ ´ëÀå±Õ, ½ÃÆ®·Î¹ÚÅ׸£¼Ó, Ŭ·¹ºê½Ã¿¤¶ó¼Ó, ¿£Å׷ιÚÅ׸£¼Ó, ÇÁ·ÎÅ׿콺¼Ó(ÇÁ ·ÎÅ׿콺 ¹Ì¶óºô¸®½º, ÇÁ·ÎÅ׿콺 ºÒ°¡¸®½º, ÇÁ·ÎÅ׿콺 ·¹Æ®°Ô¸®, ÇÁ·ÎÅ× ¿ì½º ¸ð¸£°¡´Ï), À屸±Õ, ÀÎÇ÷翣ÀÚ±Õ, ÀÌÁú±Õ, Ƽ·ç½º±Õ, ÆÄ¶óƼǪ½º±Õ ÀûÀÀÁõ ´ÙÀ½ Áúȯ¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Ù. ±Þ¸¸¼º±â°üÁö¿°, Æó¿°, ±Þ¼ººÎºñµ¿¿°, ½Å¿ì¿°, ¿äµµ¿°, ¹æ±¤¿°, ÀÓÁú
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:365000ACH ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
- ¼ºÀÎ ¹× 12¼¼ÀÌ»óÀÇ ¾î¸°ÀÌ : ÃÊȸ·®À¸·Î 4ݼ¿À» ½ÄÈÄ °æ±¸Åõ¿© Çϰí 12½Ã°£¸¶´Ù À¯Áö·®À¸·Î 1ȸ 2ݼ¿À» Åõ¿©ÇÑ´Ù.
- 6¡11¼¼
¾î¸°ÀÌ : ÃÊȸ·®À¸·Î 2ݼ¿À» ½ÄÈÄ °æ±¸Åõ¿©Çϰí 12 ½Ã°£¸¶´Ù À¯Áö·®À¸·Î 1ȸ 1ݼ¿À» Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
- ÀÌ ¾à ¶Ç´Â ¼³ÆÄÁ¦¿¡ ´ëÇÏ¿© °ú¹ÎÁõÀ» ÀÏÀ¸Ä×´ø ȯÀÚ
- ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ
- ½Å»ý¾Æ, ¹Ì¼÷¾Æ
|
| ½ÅÁßÅõ¿© |
- Ç÷¾×Àå¾Ö°¡ Àִ ȯÀÚ ¶Ç´Â Ç÷¾×Àå¾Ö¸¦ ÀÏÀ¸Ä×´ø ȯÀÚ
- °£Àå¾Ö°¡ Àִ ȯÀÚ
- ½ÅÀå¾Ö°¡ Àִ ȯÀÚ
- °í·ÉÀÚ
- º»ÀÎ ¶Ç´Â ºÎ¸ð, ÇüÁ¦°¡ ±â°üÁöõ½Ä, ¹ßÁø, µÎµå·¯±â µîÀÇ ¾Ë·¹¸£±â Áõ»óÀ» ÀÏÀ¸Å°±â ½¬¿î üÁúÀÇ È¯ÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
- Ç÷¾× :
µå¹°°Ô Àç»ýºÒ·®¼ººóÇ÷, ¹éÇ÷±¸°¨¼ÒÁõ, °ú¸³±¸°¨¼ÒÁõ, Ç÷¼ÒÆÇ°¨¼ÒÁõ, ¿ëÇ÷¼ººóÇ÷, °Å´ëÀû¾Æ±¸¼ººóÇ÷(ÃʱâÁõ»ó;¹ß¿, ÀÎÈÄÅë, ±¸³»±Ë¾ç, ÇǺÎÁ¡¸·¡¤°á¸·ÀÇ Ã¢¹é, ÀÚ¹ÝÁõ µî) À̹ݳªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
¼ï : µå¹°°Ô ¼ï Áõ»ó ( ÃʱâÁõ»ó : ºÒÄè°¨, ±¸³»ÀÌ»ó°¨, õ¸í, Çö±â, º¯ÀÇ, À̸í, ¹ßÇÑ µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ½Ç½ÃÇÑ´Ù.
ÇǺΠ: µå¹°°Ô ½ºÆ¼ºì½º-Á¸½¼ÁõÈıº, ¸®¿¤ÁõÈıº, °¡·Á¿òÁõ, ¼öÆ÷, ¹ßÁø ¶Ç´Â ±¤°ú¹ÎÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
½ÅÀå : µå¹°°Ô ½ÅÀå¾Ö ( BUNÀÇ »ó½Â, Ç÷´¢ µî )°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ ÇÏ¿© ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â °¨·®, ÈÞ¾à µîÀÇ ÀûÀýÇÑ Ã³Ä¡¸¦ ½Ç½ÃÇÑ´Ù.
½Å°æ°è : µå¹°°Ô µÎÅë, ¸»ÃʽŰ濰, Á¹À½, Çö±â µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
À§Àå : µå¹°°Ô Ç÷º¯ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. ¶Ç À§ÀåÀå¾Ö, ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä, ¼³»ç, À§ºÎ ºÒÄè°¨, ¼³¿°, ¼³ÅÂ, ºñ, ±¸°¢¿°, ±¸³»¿° µîÀÇ Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ ÀǾàǰÀÇ ÀÛ¿ëÀ» Áõ°ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
- ¼³Æù¾Æ¹Ìµå°è ¹× ¼³Æ÷´Ò¿ì·¹¾Æ°è °æ±¸´ç´¢º´¿ëÁ¦
- Äí¸¶¸°°è Ç×Ç÷¾×ÀÀ°íÁ¦.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
½ÅÀå¾Ö, °£Àå¾Ö½Ã ¿ë·®Á¶Àý |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Trimethoprim¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Trimethoprim binds to bacterial dihydrofolate reductase, subsequently interfering with the uptake of p-aminobenzoic acid (PABA) into folic acid. As folic acid is a coenzyme responsible for the transport of one-carbon fragments from one molecule to another, it is an essential component of bacterial development. Sulfonamides inhibit bacterial dihydrofolate synthetase, the enzyme immediately preceding dihydrofolate reductase, and therefore act synergistically with trimethoprim.
|
| Pharmacology |
Trimethoprim¿¡ ´ëÇÑ Pharmacology Á¤º¸ Trimethoprim, a synthetic antiinfective agent, is used to treat and prevent urinary tract infections, diarrhea, and, when combined with either sulfamethoxazole or dapsone, Pneumocystis carinii infections.
|
| Protein Binding |
Trimethoprim¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Approximately 45%
|
| Half-life |
Trimethoprim¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 8-10 hours
|
| Absorption |
Trimethoprim¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
TrimethoprimÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ : ´ëºÎºÐÀÌ ½±°Ô Àß Èí¼öµÈ´Ù.
- ´Ü¹é°áÇÕ : 42-46%
- ´ë»ç : ºÎºÐÀûÀ¸·Î °£´ë»ç
- ¹Ý°¨±â : 8-14½Ã°£, ½Å ¼Õ»ó½Ã ¿¬Àå
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 1-4 ½Ã°£ À̳»
- ¼Ò½Ç : 60-80%°¡ ¹Ìº¯Èü·Î ½Å¹è¼³
|
| Biotransformation |
Trimethoprim¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Trimethoprim¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=4850 (orally in mice)
|
| Drug Interactions |
Trimethoprim¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Trimethoprim¿¡ ´ëÇÑ Description Á¤º¸ A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the trimethoprim-sulfamethoxazole combination is the form most often used. It is sometimes used alone as an antimalarial. trimethoprim resistance has been reported. [PubChem]
|
| Drug Category |
Trimethoprim¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Infective Agents, UrinaryAnti-InfectivesAntimalarialsFolic Acid Antagonists
|
| Smiles String Canonical |
Trimethoprim¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
|
| Smiles String Isomeric |
Trimethoprim¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
|
| InChI Identifier |
Trimethoprim¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)/f/h15-16H2
|
| Chemical IUPAC Name |
Trimethoprim¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2012-03-02
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|